Shape Therapeutics (ShapeTx) is a development-stage biotechnology company establishing itself as the leader in next-generation gene therapy. Our novel technology platform enables direct in vivo targeting/modification of RNA by leveraging ADARs (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and immune-stealth adeno-associated viruses (AAVs).
ShapeTx is providing solutions to many of the challenges that contemporary genome engineering technologies face (like CRISPR, TALENs, etc.), such as permanent off-target damage, high risk of immunogenicity and therefore low in vivo applicability as effective gene therapy approaches. ShapeTx’s technology instead engages natural human cellular machinery to target RNA with high in vivo efficiency.
At ShapeTx, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases.
- Susan Byrne, PhD Principal Scientist